





CLAIMS



1. A compound having the formula:

, , or


, or a pharmaceutically acceptable salt thereof.

2. A compound of claim 1 having the formula


, , ,

, or , or a pharmaceutically acceptable salt thereof.


3. A compound of claim 1 having the formula:

, or a pharmaceutically acceptable salt thereof.

4. A compound of claim 1 having the formula:


, or a pharmaceutically acceptable salt thereof.

5. A compound of claim 1 having the formula:




, or a pharmaceutically acceptable salt thereof.

6. A compound of claim 1 having the formula:




, or a pharmaceutically acceptable salt thereof.

7. A compound of claim 1 having the formula:




, or a pharmaceutically acceptable salt thereof.

8. A compound of claim 1 having the formula:




, or a pharmaceutically acceptable salt thereof.

9. A compound of claim 1 having the formula:



, or a pharmaceutically acceptable salt thereof.

10. A compound of claim 1 having the formula:



, or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of claims 1-10, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

12. The pharmaceutical composition of claim 11, further comprising:

(i) one, two, three, or four additional therapeutic agents;

(ii) one, two, three, or four additional therapeutic agents, wherein the additional therapeutic agent or agents are anti-HIV agents.

(iii) one, two, three, or four additional therapeutic agents, wherein the additional therapeutic agent or agents are HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV capsid inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, latency reversing agents, capsid polymerization inhibitors, HIV bNAbs, TLR7 agonists, pharmacokinetic enhancers, other drugs for treating HIV, or combinations thereof; or

(iv) one, two, three, or four additional therapeutic agents , wherein the additional therapeutic agent or agents are abacavir, tenofovir alafenamide, tenofovir disoproxil, N-((*S*)-l-(3-(4-chloro-3-(methylsulfonamido)-l-(2,2,2-trifluoroethyl)-l*H*-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-l-yn-l-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3b*S*,4a*R*)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-l*H*-cyclopropa[3,4]cyclopenta[l,2-*c*]pyrazol-l-yl)acetamide, or a pharmaceutically acceptable salt thereof.

13. The pharmaceutical composition of claim 11 or 12, wherein the pharmaceutical composition is for oral or parenteral administration.

14. Use of a compound of any one of claims 1-10, or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating an HIV infection in a human having or at risk of having the infection.

15. The use of claim 14, wherein the medicament further comprisies:

(i) one, two, three, or four additional therapeutic agents;

(ii) one, two, three, or four additional therapeutic agents, wherein the additional therapeutic agent or agents are anti-HIV agents;

(iii) one, two, three, or four additional therapeutic agents, wherein the additional therapeutic agent or agents are HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV capsid inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, latency reversing agents, capsid polymerization inhibitors, HIV bNAbs, TLR7 agonists, pharmacokinetic enhancers, other drugs for treating HIV, or combinations thereof; or

(iv) one, two, three, or four additional therapeutic agents, wherein the additional therapeutic agent or agents are abacavir, tenofovir alafenamide, tenofovir disoproxil, N-((*S*)-l-(3-(4-chloro-3-(methylsulfonamido)-l-(2,2,2-trifluoroethyl)-l*H*-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-l-yn-l-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3b*S*,4a*R*)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-l*H*-cyclopropa[3,4]cyclopenta[l,2-*c*]pyrazol-l-yl)acetamide, or a pharmaceutically acceptable salt thereof.

16. The use of claim 14, wherein the medicament is for co-administration with:

(i) a therapeutically effective amount of one, two, three, or four additional therapeutic agents;

(ii) a therapeutically effective amount of one, two, three, or four additional therapeutic agents, wherein the additional therapeutic agent or agents are anti-HIV agents;

(iii) a therapeutically effective amount of one, two, three, or four additional therapeutic agents, wherein the additional therapeutic agent or agents are HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV capsid inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, latency reversing agents, capsid polymerization inhibitors, HIV bNAbs, TLR7 agonists, pharmacokinetic enhancers, other drugs for treating HIV, or combinations thereof; or

(iv) a therapeutically effective amount of one, two, three, or four additional therapeutic agents, wherein the additional therapeutic agent or agents are abacavir, tenofovir alafenamide, tenofovir disoproxil, N-((*S*)-l-(3-(4-chloro-3-(methylsulfonamido)-l-(2,2,2-trifluoroethyl)-l*H*-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-l-yn-l-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3b*S*,4a*R*)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-l*H*-cyclopropa[3,4]cyclopenta[l,2-*c*]pyrazol-l-yl)acetamide, or a pharmaceutically acceptable salt thereof.

17. The use of any one of claims 14 to 16, wherein the medicament is formulated for oral, intravenous, subcutaneous, or intramuscular administration.